Medicine background
Tirzepatide
An active ingredient acting at GIP and GLP-1 receptors.
Also discussed as: GIP GLP-1 · Mounjaro
THE RESEARCH QUESTION
What is being investigated?
Licensed medicines containing tirzepatide have defined diabetes and weight-management uses.
EVIDENCE SNAPSHOT
UK licensed medicine exists
A medicine’s approval applies to the authorised product and indication. It does not validate compounded substitutes or research-labelled powders.
LIMITS & SAFETY
What should you know?
Gastrointestinal effects and pancreatitis warnings require attention. Prescriber review is necessary.
FOLLOW THE EVIDENCE
Sources & further reading
- MHRA: GLP-1 medicines, approved uses and safety ↗UK regulator
- MHRA: strengthened warnings on pancreatitis (2026) ↗UK regulator
Checked 8 October 2026. Sources may describe different populations, formulations and jurisdictions. This overview is not a systematic review or individual medical advice.
PUT THE EVIDENCE IN CONTEXT
Questions about what you’ve read?
Request an educational conversation with Matthew about the evidence and questions to raise with your medical professional.